Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-09-10
2008-09-23
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S278000
Reexamination Certificate
active
07427623
ABSTRACT:
Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
REFERENCES:
patent: 3577420 (1971-05-01), Cronin et al.
patent: 3830813 (1974-08-01), Reuter et al.
patent: 4196207 (1980-04-01), Webber
patent: 5958930 (1999-09-01), Gangee
patent: 6001839 (1999-12-01), Rafferty et al.
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 287503 (1991-02-01), None
patent: 0082023 (1983-06-01), None
patent: 0447891 (1991-03-01), None
patent: 0447891 (1991-09-01), None
patent: 5312888 (1993-11-01), None
patent: 9841525 (1998-09-01), None
patent: 0017202 (2000-03-01), None
patent: 0119828 (2001-03-01), None
Dave, C.; Gould-Jacob type of reaction in the synthesis of thieno[3,2-e]pyrimidines: a comparison of classical heating vs solvent free microwave irradiation; Heterocycles; 1999 51(5), 1819-1826.
Robba, M.; Thienopyrimidines;Bulletin de la Societe Chimique de France, 1976, 5-6, 761-764.
Zhang, M., et al., “A concise synthetic entry to substituted 2-aminothineno '2,3-d!pyrimidines via a gewald precursor,”Bioorganic&Medicinal Chemistry Letters, vol. 7, No. 13, Jul. 8, 1997, pp. 1629-1634.
Ali, M. et al., “Synthesis of furo(2,3-d) pyrimidines and furo(3,3-b) pyridines,” Indian Journal of Heterocyclic Chemistry, 1995, vol. 4(3), pp. 191-194.
Bourguignon, J. et al., “Synthesis De Thienou2,2-Dpyrimidines Substitutes En 2 Et 4,” Bulletin De La Societe Chimiwue De France, 1975, No. 3/4, pp. 815-819.
Khachatryan, V. et al., “Synthesis, Chemical and Sntitumor Properties of Some furo(2,3-d) pyrimidines,” Khlmlcheskii Zhurnal Armenli, 199, vol. 52(1-2), pp. 95-101. (Abstract only).
McMahon, G., “VEGF Receptor Signaling in Tumor Angiogenesis,” The Oncologist, 2000, vol. 5 (Suppl. 1), pp. 3-10.
Sakamoto, T. et al., “Condensed Heteraromatic Ring Systems. VII,” Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, 1986, vol. 34(7), pp. 2719-2724.
Sun, L. et al., “Design, Synthesis and Evaluations of Substituted 3-((3- or 4-carboxyethylpyrrol-2-yl)methylidenyl) indolin-2-ones as Inhibitors of VEGF, FGF and PDGF Receptor Tyrosine Kinases,” J. Med. Chem., 199, vol. 42, pp. 5120-5130.
Ali ete al., “Synthesis of Furo[2,3-d]Pyrimidines and Furo [2,3-b]Pyridines,”Indian Journal of Heterocyclic Chemistry, vol. 4, 1995, pp. 1919-194.
Adams Jerry Leroy
Bryan Deborah Lynne
Feng Yanhong
Maeda Yutaka
Matsunaga Shinichiro
Coleman Brenda
Lemanowicz John L.
Moore Susanna
SmithKline Beecham Corporation
LandOfFree
4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3970784